Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 10 April 2015 | By Alexander Gaffney, RAC,
In the battle against the Ebola virus, perhaps no weapons have been as sought after as new treatments and diagnostic products to help keep the virus in check and patients safe from harm. But since the start of the outbreak in 2014, one regulatory standard has been an elusive goal for these medical products: Approval. To date, no product has received the full approval of the US Food and Drug Administration (FDA). Now one company is hoping to change that.
On 10 April 2015, Aethlon Medical announced it is seeking FDA approval for its Aethlon Hemopurifier under the agency's Humanitarian Use Device (HUD) pathway. The pathway, which is little known outside of regulatory circles, allows a device to be approved based on an analysis of its safety—not its efficacy—in humans.
For devices accepted for review under the HUD pathway, FDA requires the device be shown to "not expose patients to an unreasonable or significant risk of illness or injury" and demonstrate a "probable benefit to health."
The HUD pathway is only eligible for diseases which affect fewer than 4,000 patients in the US.
Read our extensive regulatory explainer on the HUD pathway here.
To date, medical products intended to treat patients with Ebola have only been made available through three regulatory pathways:
However, full approval has been elusive for products intended to treat Ebola. While many products have been used to treat the virus, few have been studied in trials, and few of those trials have been able to collect data which would easily support the approval of a product.
That's where Aethlon's HUD strategy comes into play. As explained earlier, HUD applications are designed for small populations and for devices supported by limited amounts of data. In addition, the HUD pathway is only intended for conditions where there "is no comparable device available to treat or diagnose the disease or condition." Because all other devices have been authorized for use—not approved for use—Aethlon can seek approval through this pathway.
If Aethlon's application for its bio-filtration device is accepted for review by FDA, the company should receive an approval decision within 75 days.
However, even if fully approved, there will still be some limitations on the device's use. FDA's regulations require devices approved through the HUD pathway to be used under the supervision of an institutional review board (IRB).
Aethlon has previously reported that its Hemopurifier device is currently available to patients through expanded access provisions. It has not been authorized by FDA under the agency's Emergency Use Authorization (EUA) provisions.
Aethlon Press Release
Tags: Ebola, HUD, HDE, Humanitarian Use Device, Humanitarian Device Exemption
Regulatory Focus newsletters
All the biggest regulatory news and happenings.